Brexit and the implications for UK business: Pharmaceuticals inquiry

Inquiry by the Business, Innovation, Science and Trade Committee, 20 September 2017 to 14 September 2017. Its page on the Parliament website.

Reports and responses

• 9th Report - The impact of Brexit on the pharmaceutical sector (17 May 2018)
• 11th Special Report - The impact of Brexit on the pharmaceutical sector: Government Response to the Committee’s Ninth Report (16 July 2018)

Evidence sessions

• 5 December 2017: Mike Thompson, Chief Executive, Association of the British Pharmaceutical Industry, John Smith, Chief Executive, Propriety Association of Great Britain, Paul Fleming, Technical Director, British Generic Manufacturers AssociationMark Hicken, Managing Director UK & Ireland for Janssen, Pharmaceutical Companies of Johnson and Johnson, Peter Ballard. Managing Director, Xiromed